13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuroinflammation
Neuroinflammation, on the other hand, pertains to inflammation within the central nervous system (CNS), involving immune system cells and molecules. While inflammation is a natural response to injury or infection, chronic neuroinflammation can adversely affect brain function and contribute to various neurological disorders. Microglia, the CNS's resident immune cells, are pivotal in neuroinflammation. Upon activation, microglia release pro-inflammatory molecules like cytokines, chemokines, and reactive oxygen species, potentially harming neurons and other brain cells. Astrocytes, another glial cell type, can also contribute to neuroinflammation when activated. Neuroinflammation is implicated in numerous neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, and traumatic brain injury, where chronic inflammation exacerbates neuronal damage and disease progression. Understanding the mechanisms underlying neuroinflammation is crucial for developing novel therapeutic strategies. Researchers explore various approaches to modulate neuroinflammation, including targeting specific inflammatory molecules, regulating immune cell activation, and promoting neuroprotective pathways. These efforts hold promise for developing treatments to slow or halt the progression of neuroinflammatory disorders and foster brain health.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States